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S_q Studies in animal tumour models of colorecal cancer suggst that F(ab% antibody fragments to
carcinoembryonic antigen (CEA) labeled with iodine-131 give superior therapy compared with intact anti-
CEA antibody. The purpose of this study was to investigate this hypothesis in patits. Ten patients received
intact A5B7 IgGI mouse monoclonal antibody (MAb) to CEA and nine patients received the F(ab% fragment
of the same antibody. The biodistribution for each molecuk was compared using quantitative single-photon
emission computerised tomogrphic (SPECT) gamma-camera m ng Tumour resonses wer seen in both
groups and myeos son was the limiting toxicity. F(ab% lcalsed more rapidly than intact antibody in
tumour, giving a mean perentage injected actiity per kg at 4.25 h after injection of 8.2% for F(ab%
compared with 4.4% for intact antibody (P<0.05). No significant differec in antibody clearance from, or
cumulative dose per unit administered activity (cGy MBq') to, tumour was seen. Distribution in blood was
imilar for both the intact and fragment antibody. Tbese findings are consistent with more rapid penetration of
the smaller F(ab% into tumour masses. More dient early uptake will give higher mimum dose rates to the
tumour which is valuable for radioimmunotherapy (RIT) when low dose rates may limit effectiveness of
treatmcnt. F(ab% fragments may provide a substantially enhanced method of delivering RIT.
Radioimmunotherapy (RIT) uses an antibody delivery
system to target a tumour site with radiation. A number of
beta-emitting radionuclides may be conjugated to antibody
for this treatment. Iodine 131 (131') is valable for develop-
ment of RIT because it has a beta emission of moderate
energy capable of killing tumour cells over a range of up to
40 cell diameters and a gamma emission of energy 364keV,
which can be imaged with a gamma camera for quan-
tification of biodistribution.
While it has been relatively easy to perform biodistribution
studies in experimntal animals, there has not until now been
a satisfactory way to obtain quantitative information about
antibody distribution in man. We have developed a method
for accurate quantification of 13I distribution which incor-
porates corrections for Compton scatter and attenuation
(Green et al., 1990). We have used this method to compare
two antibody preparations in the clinical development of
RIT.
RIT had produced good response rates in radiosensitive
tumours such as lymphoma when large amounts ofradionuc-
lide are given (Kaminski et al., 1993; Press et al., 1993).
However, common epitheial tumours such as colorectal and
breast carcinoma have not yet been treated so successfully
because of their greater radioresistance, which diminishes the
therpeutic ratio. In spite of this, responses to therapy have
been reported (Begent et al., 1990), and it is likely that
moderate increases in efficency in delivery of antibody-
mediated delivery of radiation could establish radioim-
munotherapy as a useful form of therapy for metastatic
colorectal carcinoma.
Intact IgG antibodies with a molcular weight (MW) of
150 kilodaltons (kDa) may not penetrate well from blood
through endothelium and extravascular tissues to the tumour
(Yokota et al., 1992). It is proposed that F(ab% antibodies
(MW 100 kDa) will achieve more effective penetration
because of their smaler molcular size and that this will
significantly improve the prospects for effective radioim-
munotherapy of colorectal cancer.
Correspondence: R.HJ. Begent
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Previous studies in animal tumour models of colorectal
carinoma have shown that F(ab% antibodies labelled with
13'I give superior tumour to blood ratios than is achieved in
therapy with intact antibody (Wahl et al., 1983; Buchegger et
al., 1990; Pedley et al., 1993). This hypothesis has been
investigated in man by comparing the F(ab% fiagment with
the intact version of the same antibody for RHT in patients
with colorectal carcinoma.
PadeUs a h
Patients
Ten patients with a raised serum CEA were given repeated
injections of '31I-labelled anti_CEA intact IgG (A5B7) (serum
CEA up to 622 sg1-', median 117.5). The next nine patients
were given '311-labelled anti-CEA A5B7 fragment F(ab'k
(serum CEA up to 390ggl-1, median 79). To suppress the
immune response to mouse IgG, cyclosporin A was given to
all patients (Lermnann et al., 1988).
All patients had unresectable, locally recurrent or meta-
static tumours and performance status 0-2 (WHO 1979
criteria) and gave written, informed consent. The study was
approved by ethics committee and covered by ARSAC
licence.
The serum level of human anti-mouse IgG antibody was
negative before therapy, assayed as described previously
(Ledermann et al., 1988). A full blood count and renal, liver
and thyroid function tests were performed at regular inter-
vals. All patients had a negative intradermal test with loig
of antibody prior to therapy. The thyroid was blocked with
potassium iodide 180mg given orally 8 hourly for 14 days
and potassium perchlorate 200mg 6 hourly for 4 days.
Details of patients are given in Table .
Anti-CEA antibody
The mouse MAb (ASB7) was raised against CEA (Harwood
et al., 1986). It was purified from supernatant culture by
protein A chromatography and shown to be free from ag-
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TaIe I Patient details
Pre Adni. actity
RIT Prinmy Previous RIT (MBq)
Patient No. twuour Age Sex Rx CEA Mean (range)
Intat
A5B7
1 4 Colon 51 M No 51 1711
2 4 Colon 50 M No 167 1960
3 2 Colon 56 M CTx 10 2720
4 3 Rectum 59 F CTx/RTx 150 1759 (251)
5 4 Rectum 43 F CTx 622 1600 (259)
6 3 Gastric 60 M CTx 546 2356 (1554)
7 2 Colon 64 M RTx 89 1702 (296)
8 2 Lung 76 F RTx/CTx 35 1906 (629)
9 2 Rectum 73 F RTx/CTx 141 962 (1258)
10 2 Colon 49 F CTx 94 1425 (555)
Fragment
I I Colon 67 M No 178 5069
2 1 Colon 57 M RTx 100 3589
3 3 Colon 49 F CTx 75 3043 (407)
4 1 Colon 60 F CTx 390 4070
5 1 Colon 65 M No <2 5476
6 1 Colon 33 F CTx 298 3441
7 1 Colon 67 M CTx 38 3996
8 1 Colon 42 M CTx 79 3101
9 2 Rectum 50 M CTx <2 3941 (555)
RTx, radiotherapy; CTx, chemodtrapy, RIT, radioimmunotherapy.
gregates by fast protein liquid chromatography (FPLC)
(Ledermann et al., 1988). Antibody production and pre-
clinical toxicology were performed in accordance with the
CRC Operation Manual (1986). The F(ab% fragment was
produced from the intact MAb A5B7 anti-CEA by digestion
with pepsin (Lamoyi & Nisonoff, 1983) and presented in a
sterile (50mM phosphate) buffer and purified by protein A
and gel filtration. Radioiodination was performed by the
N-bromosuccinamide method (Adam, 1989). This method
results in a labelling efficiency of 88-94% without loss of
immunoreactivity.
The specific activity of radiolabelling was 0.11-0.19GBq
per mg of A5B7. Details of the method of administration of
'1'I-A5B7 to patients have been reported previously (Leder-
mann et al., 1991). Repeated doses of F(ab%2 or intact
antibody of 1.2-5.5 GBq were given approximately 4 weekly.
At the start of the study 1.8 GBq was given, and this was
escalated using a Fibonacci scale to determine the maximum
tolerated dose. Further treatment was withheld ifan intrder-
mal skrin test with 10jag ofantibody became positive, if there
was more than a 4-fold increase in human IgG anti-mouse
klvd in the blood or if there was evidence ofdisease progres-
sion.
Cyclosporin A
Cyclosporin A (CsA) was given orally, 15mgkg' in two
divided doses per day (Lekemann et al., 1991), to those
patients with normal renal function, starting 2 days before
the radiolabelled antibody was administered and continuing
for a total of 14 days. Serum sampls were taken at intervals
to measure the serum CsA level and serum creatim.
Tissue andblooddata
Serial gamma-camera data were collected from 0 to 384 h
and blood data from 0 to 142 h after aministration of the
antibody. Radioactivity in blood and urine was masured
with an LKB Wizard (Pharmacia) gamma counter. Radioac-
tivity in tumour and normal tissues was estimated usng an
IGE Gemini 700 gamma camera. Serial singkl-photon emis-
sion computerised tomographic (SPECT) images were
obtained of the thorax, abdomen and pelvis and were recon-
scted usng IGE filtered backprojection software. Images
were thn corrected for Compton scatter and photon
attenuation as described by Green et al. (1990). Estimates of
serial radioactivity per unit mass (MBqkg-') in tissues post
administration were made using region of interest (ROI)
analysis on transaxial SPECT slices. The cumulative activity
(MBq h kg-') delivered by the antibody was esimated from
the area under the actvity (MBqkg-') vs time (h) curve
usng the trapezoid rule. A simplifid estimation of beta dose
(cGy) to each tissue from beta radiation contained in that
tissue was made using the MIRD absorbed dose equation:
usng S (mean dose per unit accumulated activity) = 0.3691
for '3'I (MIRD pamphkt No. 11, 1975).
Antibody distribution in tumour and normal tissue was
determined by decay correcting the measured activity
(MBqkg-') expressed as a percentage of the injected
radioactivity and plotted against time. Mean patient distribu-
tion corresponding to median gamma-camera imaging times
was estimated from the measured distribution data.
Antibody clearance was alculated by assuming a biphasic
exponential curve fit to the serial tissue and blood data. The
claanc phase is taken at greater than 24 h and data points
after 24 h used to estimate the cearance half-life (t).
Statistical analysis of the two patient groups was per-
formed uing the non-parametnc Mann-Whitney U test.
Tunour response
Evaluation of response to RIT included comparison of pre-
and post-treatment CT images of the tumour, assesment of
radiographic or ultrasound images and serum tumour marker
levels (CEA, CA19-9).
Redsm
Antibody localisation
Figure la and b shows the distribution of intact antibody
and F(ab% in blood and tumour reetively from 4.25 to
120 h post RIT adminitation. The mean percentage of the
injected activity per kilogram in tumour at 4.25 h with
antibody fragment is 8.2% compared with 4.4% for intact
antibody. Increased early loclisation is associated with the
patients receiving F(ab% compared with those receiving
intact A5B7 (P<0.05). There was substantial variation in
tumour loalisation between different patients. Figure 2
shows specific localisation in patient 3 (Table I) receiving
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the injected activity per kilogram in tumour is 18.4% at 27 h
post RIT.
Antibody clearance
The half-lives (h) for the clearance of the A5B7 intact
antibody and F(ab') in tumour, blood, liver and lung are
shown in Table II. No significant difference (P>0.05) in the
rate of clearance was found.
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Fugwe 1 a, Distribution of A5B7 intact (-) and F(ab)2 frag-
ment (0) in (a) blood and (b) in tumour. Tumour data were
derived from serial gamma-camera imaging and blood data from
gamma counting of venous blood samples.
Dosimetry
The cumulative doses to tumour, blood, liver and lung per
unit of administered activity are shown (cGy MBal) in Table
III. There appears to be no significant differences (P>0.05)
in the cumulative dose delivered for F(ab% or intact
antibody. However, higher percentage injected activity per
kilogram associated with F(ab')2 at 4.25 h will give higher
initial dose rates to the tumour.
Toxicity
Toxicity was similar in both groups (Table IV). There was
significant nausea and vomiting, together with mild abnor-
malities ofliver and renal function in both groups, which was
attributed to CsA. Myelosuppression was the significant
dose-limiting toxicity, with the nadir of platelets and
granulocytes occurring at 4-6 weeks. The maximum
tolerated dose was 2.4GBq m2. No patients were excluded
because of positive intradermal testing with antibody.
Tumour response
Responses were seen in both groups. One patient receiving
the intact antibody showed a partial response in the size of
lung metastases (Figure 3a). Complete resolution of liver
metastases was seen in one patient receiving F(ab% 4 weeks
after the first treatment, but the tumour regrew to >50% of
its original size after 8 weeks. CT scans of the liver tumour
before and after RIT are shown (Figure 3b and c).
'3'1-labelled antibody to CEA has been shown to localise well
in colonic xenografts in nude mice and to significantly inhibit
their growth (Pedley et al., 1991). Although siilar tumour-
to-normal tissues ratios are achieved in mice and humans
given the same antibody (Begent & Pedley, 1990), the
Table H Mean half-life (h) (range) oftumour and bloodclarance for
A5B7 intact and F(ab')2 antibodies
Intact F(ab')2fragment
Tumour 59.5 (90.4) 67.7 (58.6)
Blood 28.6 (23.9) 38.3 (36.0)
Table m Mean cumulative dose per unit administered activity
(cGy MBq-') (range) for A5B7 intact and F(ab)2 antibodies
Intact F(ab')2fragment
Tumour 0.029 (0.057) 0.040 (0.050)
Blood 0.028 (0.040) 0.040 (0.115)
Liver 0.016 (0.043) 0.029 (0.043)
Lung 0.008 (0.024) 0.021 (0.020)
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Fge 2 Antibody distribution data (derived from serial
gamma-camera imaging) in tumour (0) and normal tissues (0,
liver, 0, lung; x, blood) in patient no. 3 (in Table I) who reeived
intact A5B7.
Table IV Number ofpatients with toxicity from A5B7 intact (upper)
and F(ab} (lower) antibodies (% in brackets)
GI G2 G3 G4
Hb 8 (31) 4 (15) 3 (12) 1 (4)
2 (20) 2 (20) 0 1 (10)
WC 3(12) 4(15) 1 (4) 1 (4)
2 (20) 1 (10) 1(10)
PLT 1 (4) 2 (8) 2 (8) 2 (8)
1 (10) 2 (20)
N 4 (15) 3 (12) 1 (4)
4 (40)
V 3 (12) 3 (12) 1 (4)
2 (20)
Hb, haemoglobin; WC, white cell count; PLT, platelets; N, nausea; V,
vomiting.
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Figwe 3 a, Partal response m size of lung meastases in patient
no. 4 receiving intact ASB7 antibody. Sum of products in two
dimensions of three measurable hmg metastases in plain chest
radiograph. b and c, Cr scan of the liver showing a liver metas-
tasis (b) (arrowed) in patient no. 9, which resolved completely
after the first course of RIT (c) with F(ab%.
therapeutic effect is not as great in man. There may be many
reasons for this difference. Tumour volumes are larger in
patients than in mice, and it has been shown that antibody
localises less efficiently in larger tumours (Pedley et al., 1987).
Human tumour xenografts used in mice are selected for their
good loalisation of antibody, whereas there is great varia-
tion in localisation between individual patients (Boxer et al.,
1992). Neverthekss, evidence of tumour responses were seen
in the patients in this and other studies (Begent et al., 1990).
One of the limitations of RIT is the low dose rate achieved
in the tumour. It has been estimated that, below a certain
threshold dose rate, tumour growth rate will exceed cell kill
rate (Fowler, 1990). Hence, an increase in the dose rate
delivered by RIT may be critical for successful therapy. It is
possible that a relatively modest improvement in antibody
locaistion in tumour relative to normal tissue could pro-
duce a marked improvement in clnical response. F(abj2, by
potentially doubling the maximum dose rate for the same
administered radioactivity and toxicity, may give a substan-
tal improvement in therapeutic sucess.
Pedley et al. (1993) have demonstrated that twice the
activity of F(ab% radioantibody must be admini in
order to produce similar therapeutic effects with the F(ab%2
fragment as the intact antibody. This is due to more rapid
circulatory clearance of the fragment during the initial few
hours in mice, resulting in a lower absolute amount delivered
to the tumour. In addition Pedley et al. (1993) showed that
tumour-to-normal tissue ratios were higher and toxicity was
reduced with F(ab%. Reduced toxicity is important, as it
may allow for an increase in the amount of radioactivity
delivered to the tumour in clinical RIT. Human bone mar-
row has a lower tokrance for radiation than that of mic
(Badger et al., 1985; Bigler et al., 1986; Buchegger et al.,
1990) and is the main dose-limiting toxcity in RIT. Severe
immediate-type hypersensitivity reactions occasionally occur
after administration of murine antibodis, and this was the
reason for intradermal testing with antibodes before int-
ravenous administration. While this carries a risk of inducing
sensitisation to antibody, ensuring a negative intadermal test
is the safest course in terms of reducing the risk of severe
immediate-type hypersensitivity. IgG human anti-mouse
antibody develops very commonly after murine antibody
administration whether intradermal testing is done or not.
The distribution data presented here do not show the same
pattern of rapid circulatory clarance of F(ab% antibody
seen in the xenograft model. This is consistent with the
similar bone marrow toxicty in the two groups of patients
considering that circulating radioactivity is believed to be the
source of bone marrow suppression.
The more rapid clearance of F(ab%2 than intact antibody
in mice is usually associated with high renal uptake of
radioactivity simila to that seen when Fab' is given. Fab'
(50kDa) is smIall enough to be filtered by glomeruli and
reabsorbed in the renal tubules. Renal uptake of F(ab32
would not be expected if it remains intact at 100 kDa MW,
but could be exlained in mice by its being broken down in
mouse serum to Fab' while the preparation used here re-
mains stable as F(ab% in the crculation in man.
The similar distibution of intact and F(ab)2 antibody in
the circulation and liver refutes the hypothesis that clearance
of the intact antibody is substanially mediated by Fc rep-
tor binding- This is consistent with the low affinity of
monomenc IgG for the Fc receptor, in contrast to the greatly
increased affinity of aggregates (Arend & Mannikr 1972).
The data presented are the first in patients to suggest a
more rapid penetration of the F(ab% into tumours as com-
pared with intact antibody. It is proposed that the faster
penetration of the fragment is the result of its smaler
mokcular weight, and this is consient with the finding that
small molcular size in antibodies results in improved pene-
tration in tumour animals models (Yokota et al., 1992) and
in tumour spheroids (Sutherland et al., 1987; Sunters et al.,
1992). Sunters et al. (1992) showed that further reductions in
molecular size of antibody may produce even more rapid
tumour penetration. In animal model studies F(ab% cleared
more rapidly from the circulation than intact antibody, mak-
ing it difficult to assess the contribution ofmolcular size to
tumour uptake since uptake is in part dependent on the
availability of antibody in the circulation.
The observations in our study make it possible to see the
effect of reducing moleular size on tumour penetration in
man because the clarance from pLam of the F(ab% and
intact antibody was very similar. Mocules smaler than
F(ab% can be expected to clear more rapidly than F(ab% in
man, with the result that the absolute amount of antibody
delvered to the tumour will probably be less. F(ab)2 may
therefore be a good compromise as a therapeutic molecule,
giving high absolute amounts ofradioantibody in the tumour
with rapid penetration.RADIOIMMUNOTHERAPY WITH INTACT AND F(ab'), ANTIBODIES 525
The overall improvement in initial uptake and therapeutic
ratio associated with the administration of the F(ab')2
antibody has important implications for the future design of
antibody-targeted therapy.
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